An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

Autor: Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)

Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re

Externí odkaz: https://doaj.org/article/4608673a241f46ca9625955f197bdebe

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study

Autor: James Welker, Juan D Pulido, Andrew T Catanzaro, Carlos D Malvestutto, Zihai Li, Jonathan B Cohen, Eric D Whitman, Dana Byrne, Olivia K Giddings, Jordan E Lake, Joel V Chua, Ella Li, Jian Chen, Xiang Zhou, Kun He, Davis Gates, Amarjot Kaur, Jamie Chen, Hung-Yen Chou, Martin Devenport, Raymond Touomou, Shyamasundaran Kottilil, Yang Liu, Pan Zheng, Jai Thakor, Imaan Khan, Nicole Do, Josephine Faragalla, Andrea Hook, Sarah Kern, Janira V. Ramos, Jason Ward, John Higson, Meena Dam, Dawn Serkin, Pooja Karloopia, Wendy Moore, Mark Scofield, David Jeffery Childers, Jeffrey S. Cantrell, Millie Corgan, Jing Liu, Denise Redvers-Higgins, Hua Han, Jiyun Hou, Yudi Pan, Karyn Tucker, Xiaoyan Zhang, Joel V. Chua, Jennifer Husson, Shivakumar Narayanan, Jaqueline Bran, Ka Wing Joyce Lam, Alicia Jeffrey, Olivia K. Giddings, Jennie Pexa, Mario Becerra, Kathleen W. Gray, Nicole Richmond, Chukwuemeka Nzelibe, Carlos D. Malvestutto, Susan Koletar, Mahdee Sobhanie, Jan Clark, Kelsi Reynolds, Karthik Chakravarthy, Kevin Weller, Mohamed Yusuf, Jennifer Severing, Kelley Barley, Juan D. Pulido, Jennifer C. Fulton, William Gil, M.D. Jeanine, Richmond R.N., Sandy Jones, Kristina Clemmer, Lisa Pedroza, Emily Nicole Davidson, Amanda Logan, Katie Grant, Eric D. Whitman, Jason Kessler, Robert Roland, Rosemary Stefiniw, Molly Maurer, Salome Geene, Christopher F. Buck, Debra Connolly, Patrice Light, Sunanda Baviskar, Yee Won Low, Kyra Michalski, Pamela Giordano, Jennifer Chao, Michelle Williams, Amulya Makkapati, Andrew T. Catanzaro, Jonathan B. Cohen, Mehad Musbah, Pramila Jaladanki, Ying Yuan, Shilpa Rele, Desirae Stewart, Starlet Lewis, Ian Sankar, Nabulungi Kasumba, Kaylia Biney, Elham Hekmat, Jordan E. Lake, Bindu Akkanti, Melissa J. Reimer-McAtee, Marisel Negret Hernandez

Publikováno v: The Lancet. Infectious diseases. 22(5)

Non-antiviral therapeutic options are required for the treatment of hospitalised patients with COVID-19. CD24Fc is an immunomodulator with potential to reduce the exaggerated inflammatory response to tissue injuries. We aimed to evaluate the safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6942fc252d729f16df5ccd60b55adb2f
https://pubmed.ncbi.nlm.nih.gov/35286842

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma

Autor: Eric D. Whitman, Meihua Wang, Howard L. Kaufman, Praveen K. Bommareddy, Lynn E. Spitler, Cai Wu, Karl Zhou, Robert H.I. Andtbacka, Gregory A. Daniels, Brendan D. Curti, Mark Grose, Sigrun Hallmeyer, Jose Lutzky

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(34)

PURPOSEWe evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma.PATIENTS AND METHODSIn this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c64a2e7ccfdde694f43a25e13e38101
https://pubmed.ncbi.nlm.nih.gov/34464163

Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction

Autor: Vadim P. Koshenkov, Robert W. Cook, John T. Vetto, Paul Toomey, Eddy C. Hsueh, Ann P. Quick, Olga Zolochevska, Andrew Ward, Robert S. Davidson, Kyle R. Covington, J. Michael Guenther, Thomas P. Trezona, Matthew S. Goldberg, Peter D. Beitsch, Franz O. Smith, Michael McPhee, Parth K. Shah, David M Hyams, Eric D. Whitman, James M. Lewis, Martin D. Fleming, Brian R. Gastman, Shawn E. Young, Federico A Monzon, Brian Martin, Deri Lewis, Ho Pak

Publikováno v: JCO Precision Oncology

PURPOSE National guidelines recommend sentinel lymph node biopsy (SLNB) be offered to patients with > 10% likelihood of sentinel lymph node (SLN) positivity. On the other hand, guidelines do not recommend SLNB for patients with T1a tumors without hig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c84e621d7ecd38ea2b3d248901612c
https://pubmed.ncbi.nlm.nih.gov/34568719

799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

Autor: Christopher Stuart Baker, Jack Lee, Tom Van Hagen, Victoria Atkinson, Bernard A. Fox, Carmen Ballesteros-Merino, Eric D. Whitman, Kellie Malloy Foerter, Reneta Hermiz, Sajeve Thomas, Scott J. Diede, Elizabeth Buchbinder, Katy K. Tsai, Catalin Mihalcioiu, Shawn M. Jensen, Rachel Roberts-Thomson, Sandra Aung, David A. Canton, Alain Algazi, Christopher G. Twitty, Mecker G. Möller, Clemens Krepler, Donna Bannavong, Emmett V. Schmidt, Marcus O. Butler, John R. Hyngstrom, Erica Browning, Jon Salazar, M. Shaheen, Adil Daud, Matteo S. Carlino, Andrew Mant, C. Lance Cowey, Gregory A. Daniels, Lauren Svenson, Pablo Fernandez-Penas, Igor Puzanov, Jendy Sell, Andrew Haydon

Publikováno v: Late-breaking abstracts.

Background Electroporated plasmid IL-12 (TAVO or tavokinogene telseplasmid) is a novel pro-inflammatory intratumoral therapy with substantial single agent activity in melanoma, which has been shown to synergize with anti-PD-1 antibodies in patients p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33061585f71cc99fe4548a1d89e71632
https://doi.org/10.1136/jitc-2020-sitc2020.0799